Oncaspar liquid (pegaspargase) / Servier - LARVOL DELTA

A phase 2 study evaluating the safety and efficacy of first line asparaginase recombinant erwinia asparaginase (Rylaze) during pediatric-inspired regimen in high-risk adults with newly diagnosed ALL or lbl (ASH 2025) - P2 | "Background and Significance: Pegaspargase-based therapy for acute lymphoblastic leukemia (ALL) offers well-established benefits but treatment-related toxicity precludes its widespread adoption. If our study demonstrates the tolerability and safety of using frontline recombinant Erwinia asparaginase during induction in high-risk adults with ALL, this approach could potentially establish it as the first-line asparaginase in this population and support its use in subsequent treatment cycles. Acknowledgements:This study is financially supported by Jazz Pharmaceuticals, which also conducted a courtesy medical review of this abstract."

Clinical • P2 data • Acute Lymphocytic Leukemia • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Obesity • Pancreatitis • Pediatrics • Thrombosis

Efficacy and safety of mitoxantrone hydrochloride liposome combined with pegaspargase in the treatment of extranodal NK/T-cell lymphoma (ASH 2025) - "The regimen combining PLM60 with pegaspargase demonstrates high ORR and DCR in treating extranodal NK/T-cell lymphoma. Adverse events were primarily hematologic toxicities, which were manageable overall. The regimen exhibits a favorable safety profile, thereby providing a new effective treatment option for ENKTL patients."

Clinical • Epstein-Barr Virus Infections • Extranodal Natural Killer/T-cell Lymphoma • Gastrointestinal Disorder • Immunology • Infectious Disease • Leukopenia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia (ASH 2025) - P2 | "These findings provide a strong rationale for combining ruxolitinib with P-Gemox (pegaspargase, gemcitabine, and oxaliplatin) to improve outcomes in ANKL. This regimen appears to be an effective and well-tolerated induction strategy while bridging to allo-HSCT. These preliminary findings warrant further evaluation in larger, prospective studies."

Clinical • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Fibrosis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Influenza • Leukemia • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases

GWAS-guided pharmacogenomic risk scores predict premedication-related pegaspargase hypersensitivity and toxicities in pediatric and adolescent young adults with acute lymphoblastic leukemia or lymphoma (ASH 2025) - "Our results describe the GWAS-guided development of polygenic risk scores predicting PEG hypersensitivity and toxicity incidences. This approach eliminates certain biases associated with a candidate selection approach to build pharmacogenomic risk scores. Validation of these scores in a similar cohort as well as functional validations will be performed in the near future."

Biomarker • Clinical • Acute Lymphocytic Leukemia • Dyslipidemia • Hematological Malignancies • Hepatology • Hypertriglyceridemia • Hypoglycemia • Immunology • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Pancreatitis • Pediatrics • T Acute Lymphoblastic Leukemia • Thrombosis

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia (ASH 2025) - "Methods This retrospective analysis included adult patients with newly diagnosed ALL who were treated at City of Hope (COH) and received pegaspargase as part of their induction regimen...Future studies and novel interventions including lifestyle and pharmaceutical therapies are warranted in this patient population and could improve induction outcomes and disease response as previously shown in other populations such as in the IDEAL study (Orgel et al. Blood Adv 2021)."

Clinical • Acute Lymphocytic Leukemia • Diabetes • Genetic Disorders • Hematological Malignancies • Hepatology • Leukemia • Obesity

Associations between serum asparaginase activity and asparaginase-associated toxicities in pediatric ALL patients receiving calaspargase: A report from the DFCI ALL consortium (ASH 2025) - "Aserum asparaginase activity (SAA) of 0.1 IU/mL is associated with therapeutic effect; however, for severalweeks after a dose of pegylated E.coli asparaginase formulations (pegaspargase or calaspargase), SAAlevels exceed this threshold...Among patients receiving calaspargase for ALL, we found no association between high NSAA levels andASP-related toxicity; NSAA levels were also not associated with demographic or disease characteristics.These results suggest that decreasing SAA via dose reduction or capping calaspargase doses may notreduce the rate of ASP-related toxicity. While our findings warrant further exploration to determine theutility of NSAA level as a predictor of toxicity risk, other potential risk factors for, and interventions toprevent, ASP-related toxicities should also be examined."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Hepatology • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Pancreatitis • Pediatrics

Selinexor combined with pegaspargase and dexamethasone, followed by radiotherapy, for newly diagnosed stage I–II natural killer/T-cell lymphoma: A multicenter, single-arm, Phase I/II study (ASH 2025) - P1/2 | "This regimen demonstrated high preliminary efficacy in newly diagnosed stage I–II NKTCL,with simple administration and short hospitalization. While generally tolerable, vigilant monitoring andsupportive care are needed to mitigate adverse events."

Clinical • P1/2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Pancreatitis • T Cell Non-Hodgkin Lymphoma

Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia (ASH 2025) - P4 | "Eligibility criteria included: (1) intermediate-risk (MR) with MRD ≥1% bymultiparametric flow cytometry (MFC) at day 15; or (2) high-risk (HR) per the Chinese Children's LeukemiaGroup 2018-ALL (CCLG-2018-ALL) criteria at day 15.All patients received a reduced-intensity induction chemotherapy: daunorubicin (2 doses), vincristine (2doses), pegaspargase (1 dose), and prednisone about 2 weeks. ConclusionIn Chinese children with intermediate- or high-risk BCP-ALL, integrating blinatumomab after a reduced-intensity induction chemotherapy achieves high rates of deep molecular remission with a favorablesafety profile. These findings support the potential of immunotherapy-driven frontline strategies toimprove early outcomes and reduce long-term toxicity in pediatric BCP-ALL."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Infectious Disease • Pancreatitis • Septic Shock • ABL1 • DUX4 • ETV6 • KMT2A • MEF2D • RUNX1

Clinical characteristics and outcomes of cerebral venous sinus thrombosis in hematologic malignancy patients pre- and post-hematopoietic stem cell transplantation: A single-center retrospective study in China (ASH 2025) - "WhileHSCT offers curative potential for hematologic diseases, its associated prothrombotic risks—includingconditioning regimens, immunosuppressive therapy (e.g., cyclosporine), and graft-versus-host disease(GVHD)—may exacerbate CVST susceptibility. Pegaspargase-based regimens significantly elevate CVST risk in ALL management. The post-HSCT CVSTmay be associated with calcineurin inhibitor toxicity (early phase), cGVHD pathophysiology (chronicphase), and disease relapse. Most patients demonstrate favorable outcomes with appropriateanticoagulation therapy."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cardiovascular • Cerebral Hemorrhage • Chronic Graft versus Host Disease • CNS Disorders • Epilepsy • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Septic Shock • Thrombocytosis • Thrombosis • Transplantation

Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism (ASH 2025) - "Pegaspargase was the mostcommon asparaginase used (91%).Index VTE occurred at a median of 75 days (IQR: 25-182) following ALL diagnosis...The preferred initial agent was enoxaparin (101/106, 95%) and medianduration of anticoagulation was 6.4 months (IQR: 3.2-9.5)... VTE progression/recurrence following a first VTE occurred in 17% of children andadolescents with ALL. In this retrospective analysis, extended anticoagulation was not associated with areduced risk of VTE progression/recurrence. This could suggest that an extended anticoagulationapproach is not more effective or could reflect confounding by indication where patients considered athigher risk of progression/recurrence received longer antithrombotic treatment."

Clinical • Acute Lymphocytic Leukemia • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Venous Thromboembolism

Metabolic and genetic determinants of severe asparaginase toxicities in adolescent and young adult acute lymphoblastic leukemia. (ASH 2025) - "Anaphylaxis was rare (3 cases), all occurring after IM administration of E. coli L-asparaginase despite premedication.Independent risk factors identified in multivariate analysis were:Hypertriglyceridemia: BMI >24 kg/m² (OR 2.51, p28 kg/m² (OR 1.13, p25 kg/m² (OR 3.92,p<0.001)Thrombosis: concomitant glucocorticoids (OR 3.70, p=0.035)There were no significant toxicity differences between E. coli L-asparaginase and pegaspargase.To account for multiple cycles per patient, we used mixed-effects logistic regression...PNPLA3 rs738409 increasedthe risk of hypertriglyceridemia, while APOA5 rs662799 appeared protective against hepatotoxicity,suggesting gene-specific effects on lipid metabolism. These findings underscore the need forpersonalized metabolic monitoring and supportive care strategies in AYA patients treated withasparaginase."

Clinical • Acute Lymphocytic Leukemia • Diabetes • Dyslipidemia • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertriglyceridemia • Leukemia • Liver Failure • Obesity • T Acute Lymphoblastic Leukemia • Thrombosis • APOA5 • APOE • PNPLA3

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol (ASH 2025) - P1/2 | "MethodsIn this prospective long-term follow-up study of the RJ-ALL 2014 protocol, 153 newly diagnosed patients(pts) with BCR::ABL1-negative B-ALL received intensive treatment with 14 injections of pegaspargase (p-asa) throughout the entire course (2 for induction, 4 for consolidation, 8 for maintenance) : the inductionwith VIPCP regimen (vincristine, idarubicin, p-asa, cyclophosphamide, methylprednisolone), theconsolidation with hyper-CVAD (from MD. Anderson) plus p-asa alternating with high dose methotrexateand cytarabine, and the maintenance with POMP (from BFM protocol) plus p-asa...HSCT is a protective factor for the prognosis in multiple multivariateanalysis. Our data suggest that 3-month MRD statutes is important in predicting 10-year survivaloutcome."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • T Acute Lymphoblastic Leukemia • ABL1 • DNMT3A • KIT • KMT2A

Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia (ASH 2025) - "However, numerical differences seen in rates ofpancreatitis and cerebral venous thrombosis may warrant further investigation. Future prospectivestudies are needed to determine the optimal PEG-ASP dosing for AYA patients, as well as which patientsmay benefit from empiric dose modifications."

Clinical • Acute Lymphocytic Leukemia • Diabetes • Dyslipidemia • Genetic Disorders • Hematological Malignancies • Hepatology • Hypertriglyceridemia • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Metabolic Disorders • Obesity • Pancreatitis • T Acute Lymphoblastic Leukemia • Type 2 Diabetes Mellitus • Venous Thromboembolism

Daratumumab and venetoclax-based combined regimen for relapsed/refractory T-lymphoblastic leukemia/lymphoma (ASH 2025) - "Additionally, some patients received liposomal mitoxantroneand pegaspargase as part of their treatment. The combined regimen of Dara and Ven achieved an overall response rate (ORR) of 75.0%, with acomplete remission (CR) rate of 58.8%. The Dara and Ven regimen demonstrates a high response rate and well-tolerated treatmentoption for patients with relapsed/refractory T-ALL/LBL. It can serve as a bridging treatment for patientswho have not undergone allo-HSCT. For patients who experience relapse after allo-HSCT, it can also beused as a maintenance therapy to extend disease-free survival."

Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • T Acute Lymphoblastic Leukemia

MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL (ASH 2025) - "Our study suggests that combining the FDA-approvedPI3Kγ/δ inhibitor, Duvelisib, with CAR-T therapy holds significant promise for the treatment of R/R B-ALL.Furthermore, we identified NADH accumulation as a key metabolic vulnerability in R/R B-ALL, renderingthese cells susceptible to reductive stress enhancing treatment and glutamine derivation. Notably,Pegaspargase is particularly important for treating R/R B-ALL, and here we report that combiningPegaspargase with a potent complex I inhibitor IACS, which impairs NADH oxidation process, exhibitssignificant therapeutic effects on mice with PI3KhiMYCamp B-ALL.ResultsBy analyzing cancer cohorts based on transcription profiles indicative of PI3K and MYC activity, we foundunlike their established roles as individual prognostic indicators in other cancers, neither PI3K nor MYCactivity alone robustly predicts B-ALL prognosis...Additionally,PI3KhiMYCamp serves as a prognostic marker, identifying B-ALL patients with poor outcomes...."

IO biomarker • MYC • PIK3CG

Clinical Characteristics and Outcomes of Infant Acute Lymphoblastic Leukemia from a Single Institute in China (ASH 2024) - "Among these, 13 patients received 4-week VDLD induction (vincristine, daunorubicin, L-asparaginase/pegaspargase, dexamethasone), 1 patient was treated with 2-week venetoclax and 5-day azacytidine, 1 patient received 2-week VP (vincristine, dexamethasone) and 2-week blinatumomab, and 2 patients underwent 4-week VDLV induction (vincristine, dexamethasone, pegaspargase, venetoclax). Conclusions : IALL patients frequently have KMT2A-R and exhibit high relapse rates and poor prognosis. Considering the toxicity associated with intensive induction chemotherapy, combining reduced-intensity chemotherapy with blinatumomab may provide a more cost-effective therapeutic strategy."

Clinical • Acute Lymphocytic Leukemia • Agranulocytosis • Granulocytopenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • AFF2 • CD19 • KMT2A • MME

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial (ASH 2024) - P3 | "Eligible pts received the CALGB 10403 regimen modified to omit extended induction, include dexamethasone as opposed to prednisone as steroid backbone, cap the pegaspargase dose to 3750 units, and adding rituximab for pts with CD20 expression (> 20%). INO may still be efficacious if late toxicity can be mitigated. A pilot study is planned that will decrease INO dose, add 2 cycles of blinatumomab and strict infectious prophylaxis guidelines."

Clinical • P3 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • Septic Shock • ABL1 • CD20 • CD22

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial (ASH 2023) - " Patient between the ages of 30 and 70 with newly diagnosed BCR::ABL1 negative B-lineage ALL were enrolled and initially received 2.5 months of combination induction chemo utilizing a BFM-like regimen adapted from the E2993/UKALLXII clinical trial, with pegaspargase (after induction only for patients >=55 years of age) and addition of rituximab for CD20 positive patients... The addition of blinatumomab to consolidation chemotherapy resulted in a significantly better overall survival compared to chemotherapy alone in pts with newly diagnosed B-lineage ALL who were MRD negative after intensification. This represents a new standard of care for pts aged 30-70 years with BCR::ABL1 negative ALL. The optimal dose and number of cycles is however unknown."

Clinical • P3 data • Residual disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD20

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience (ASH 2024) - "Similar to pediatric regimens, AHCVAD uses intensified doses of vincristine, dexamethasone, and pegaspargase and shows activity in relapsed pts with ALL (Faderl S et al : Clin Lymphoma Myel Leuk 2011)...Pts with CD20+ ALL also received Rituximab at 375 mg/m2 on days 1 and15 of cycles 1 to 4. In pts with T-ALL, two cycles of Nelarabine were given following AHCVAD cycles 4 and 5, respectively, and repeated during maintenance cycles 12 and 24...Those who didn't achieve MRD negativity after 2 cycles were switched to blinatumomab or inotuzumab ozogamicin...The augmentation of the hyper-CVAD backbone in this fashion may be more feasible in the community setting than other pediatric protocols. However, intensive monitoring with appropriate antibiotic, antiviral prophylaxis and growth factor support is required given significant toxicities observed."

Clinical • Minimal residual disease • Acute Lymphocytic Leukemia • Burkitt Lymphoma • Cardiovascular • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • Thrombosis • Transplantation • ABL1 • BCR • CD20

AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Children's Oncology Group | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD22

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL (ASH 2024) - "Patients with R/R and de novo T-ALL were enrolled in this study and received BEAT chemofree regimen including venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14), tucidinostat and dexamethasone (10 mg on days 1-14) and pegaspargase (2000IU on day 3). The most common grade 3-4 AEs of de novo T-ALL were neutropenia (83%), anemia (67%), thrombocytopenia (34%), febrile neutropenia (17%), lung infection (17%) and ALT increased (17%). There were no gastrointestinal disorders of grade 3-4 or serious AEs of grade 5.Conclusion : BEAT chemofree regimen is a promising and well-tolerated regimen in R/R and de novo T-ALL, with high CRc and ORR."

Acute Lymphocytic Leukemia • Anemia • Endocrine Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pediatrics • Respiratory Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombocytopenia • CD7

Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. (PubMed, J Clin Oncol) - "Additional PEG-ASNASE in phase IB did not translate into a benefit for decreasing relapse incidence but was associated with higher toxicity. Further improvements with conventional chemotherapy might be difficult in the context of intensive treatment protocols."

Journal • B Acute Lymphoblastic Leukemia • Oncology • T Acute Lymphoblastic Leukemia • AFF1 • KMT2A

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma (ASH 2024) - P2 | "The patients had high CRR, PFS rate, OS rate and controllable adverse reactions. (NCT04414969)"

Clinical • Combination therapy • P2 data • Anemia • Extranodal Natural Killer/T-cell Lymphoma • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Efficacy and Safety of Combined Anti-PD-1, Bortezomib and Pegaspargase Regimen for Newly Diagnosed Early Stage Extranodal NK/T-Cell Lymphoma (ASH 2024) - P2 | "L-asparaginase-based treatment regimens, such as SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide), DDGP (dexamethasone, cisplatin, gemcitabine,and pegaspargase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown higher response rate and survival outcomes than traditional anthracycline-containing regimen...Treatment included 6 cycles of PPB : intravenous tislelizumab (200mg, d1), subcutaneous bortezomib (1.3mg/m2, d1,4,8,11) and intramuscular pegaspargase (2500 IU/m2, d1), and repeated every 3 weeks...In this single arm clinical trial, the PPB regimen showed promising preliminary results with tolerable side effects. A confirmation trial based on larger population is needed in the future."

Clinical • Anemia • Extranodal Natural Killer/T-cell Lymphoma • Hematological Disorders • Hematological Malignancies • Liver Failure • Lymphoma • Natural Killer/T-cell Lymphoma • Nephrology • Neutropenia • Oncology • Renal Disease • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

Addition of Chidamide to a Sandwich Protocol, Pegaspargase, Gemcitabine and Oxaliplatin Chemotherapy Combined with Radiotherapy, As First-Line Treatment in Early Stage NK/T-Cell Lymphoma: Real World Outcomes in a Retrospective Study (ASH 2023) - "Recently, Xue et al showed that chidamide in combination with cisplatin, etoposide or gemcitabine showed synergistic effect and reversed the chemotherapy resistance in the relapsed/refractory B-cell lymphoma. This study demonstrates that sandwich CP-GEMOX chemoradiotherapy is a safe and promising approach to managing patients with early-stage ENKTL-NT."

Real-world • Real-world evidence • Retrospective data • Anemia • B Cell Lymphoma • Dental Disorders • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Infectious Disease • Lymphoma • Mucositis • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pancreatitis • Pneumonia • Respiratory Diseases • Septic Shock • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Xerostomia • B2M